Tevogen Inc. Operating Expenses
Tevogen Inc. (TVGN) reported Operating Expenses of $5.66 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-14
- Tevogen Inc. operating expenses for the quarter ending 2026-06-30 was $5.66M, a 4.00% increase year-over-year.
- Tevogen Inc. operating expenses for the quarter ending 2026-03-31 was $5.40M, a 47.85% decline year-over-year.
- Tevogen Inc. operating expenses for the quarter ending 2025-12-31 was $4.61M, a 50.76% decline year-over-year.
- Tevogen Inc. operating expenses for the quarter ending 2025-09-30 was $5.73M, a 5.85% decline year-over-year.
- Tevogen Inc. operating expenses for fiscal 2025 was $26.14M, a 51.20% decline from fiscal 2024.
- Tevogen Inc. operating expenses for fiscal 2024 was $53.56M, a 505.73% increase from fiscal 2023.
- Tevogen Inc. operating expenses for fiscal 2023 was $8.84M.
| Period end | Operating Expenses 3 month | Operating Expenses 5 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $5.66M 10-Q · filed 2026-08-14 | $11.06M 10-Q · filed 2026-08-14 | $15.67M derived: sum of 3 quarters · filed 2026-08-14 | $21.40M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | $5.40M 10-Q · filed 2026-05-15 | $10.01M derived: sum of 2 quarters · filed 2026-05-15 | $15.74M derived: sum of 3 quarters · filed 2026-05-15 | $21.19M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | $4.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $10.34M derived: sum of 2 quarters · filed 2026-03-31 | $15.78M derived: sum of 3 quarters · filed 2026-08-14 | $26.14M 10-K · filed 2026-03-31 | |
| 2025-09-30 | $5.73M 10-Q · filed 2025-11-14 | $11.17M derived: sum of 2 quarters · filed 2026-08-14 | $21.53M 10-Q · filed 2025-11-14 | $30.89M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | $5.44M 10-Q · filed 2026-08-14 | $15.80M 10-Q · filed 2026-08-14 | $25.16M derived: sum of 3 quarters · filed 2026-08-14 | $31.25M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | $10.36M 10-Q · filed 2026-05-15 | $19.72M derived: sum of 2 quarters · filed 2026-05-15 | $25.81M derived: sum of 3 quarters · filed 2026-05-15 | $34.40M derived: sum of 4 quarters · filed 2026-05-15 | |
| 2024-12-31 | $9.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $15.45M derived: sum of 2 quarters · filed 2026-03-31 | $24.05M derived: sum of 3 quarters · filed 2026-03-31 | $53.56M 10-K · filed 2026-03-31 | |
| 2024-09-30 | $6.09M 10-Q · filed 2025-11-14 | $14.68M derived: sum of 2 quarters · filed 2025-11-14 | $44.20M 10-Q · filed 2025-11-14 | $46.21M derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | $8.60M 10-Q · filed 2025-08-14 | $38.12M 10-Q · filed 2025-08-14 | $40.13M derived: sum of 3 quarters · filed 2025-08-14 | $42.45M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $29.52M 10-Q · filed 2025-05-14 | $31.53M derived: sum of 2 quarters · filed 2025-05-14 | $33.85M derived: sum of 3 quarters · filed 2025-05-14 | $36.04M derived: sum of 4 quarters · filed 2025-05-14 | |
| 2023-12-31 | $2.01M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-02 | $4.33M derived: sum of 2 quarters · filed 2025-04-02 | $6.52M derived: sum of 3 quarters · filed 2025-04-02 | $8.84M 10-K · filed 2025-04-02 | |
| 2023-09-30 | $2.33M 10-Q · filed 2024-11-19 | $4.51M derived: sum of 2 quarters · filed 2024-11-19 | $6.83M 10-Q · filed 2024-11-19 | ||
| 2023-06-30 | $2.18M 10-Q · filed 2024-08-14 | $4.51M 10-Q · filed 2024-08-14 | |||
| 2022-09-30 | $198.83K 10-Q · filed 2022-11-14 | $740.30K 10-Q · filed 2022-11-14 | |||
| 2021-09-30 | $115.00 10-Q · filed 2022-11-14 | $11.41K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B |